Gyre Therapeutics (GYRE) AI Stock Analysis

• Market Cap: $745.91M
• Dividend Yield: N/A
• Average Volume (3M): 225.26K
• Price to Earnings (P/E): 73.8
• Beta (1Y): 1.07
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 579
• Sector: Healthcare
• Sector Strength: 64
• Industry: Biotechnology
• EPS (TTM): 0.12
• Shares Outstanding: 86,332,214
• 10 Day Avg. Volume: 166,649
• 30 Day Avg. Volume: 225,259
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 8.65
• Price to Cash Flow (P/CF): 131.70
• P/FCF Ratio: 192.70
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $20.00
• Price Target Upside: 117.63% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Gyre Therapeutics faces significant challenges, particularly in financial stability and valuation. The company's operational efficiencies show improvement, yet revenue volatility and cash flow issues raise concerns. Technical indicators reflect mixed signals, with potential bearish momentum. The high P/E ratio indicates overvaluation, and the lack of a dividend yield may deter some investors. These elements collectively result in a modest stock score.

Gyre Therapeutics Business Overview & Revenue Model

Company Description

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

How the Company Makes Money

Gyre Therapeutics Financial Statement Overview

Summary

Gyre Therapeutics' financial performance shows mixed results. While the company has improved operational efficiencies, as seen in better EBIT and EBITDA margins, revenue growth remains volatile. The balance sheet is strengthening with a solid equity base, but past volatility in equity levels is concerning. The cash flow statement indicates liquidity challenges, with negative free cash flow and inconsistent operating cash flow.

Income Statement

Gyre Therapeutics has shown inconsistent revenue growth, with a significant drop from 2023 to 2024. The gross profit margin remains high, indicating efficient production costs, but the net profit margin is volatile due to fluctuating net income. The EBIT and EBITDA margins have improved over the years, reflecting some stabilization in operational efficiency.

Balance Sheet

The company's balance sheet shows a strong equity base as of 2024, with a favorable debt-to-equity ratio indicating low leverage. However, the past volatility in stockholders' equity, including negative equity in 2023, could pose a risk. The equity ratio is strong, showing a good proportion of assets financed by equity.

Cash Flow

Cash flow from operations has been inconsistent, with a significant negative figure in 2024. Free cash flow has also been negative, raising concerns about liquidity. The operating cash flow to net income ratio is concerning due to negative operating cash flow, indicating potential cash management issues.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
105.76M	113.45M	794.00K	7.34M	20.95M
	Gross Profit
101.87M	108.81M	-4.00K	-42.00K	11.79M
	EBIT
16.16M	-67.23M	-8.61M	-87.89M	-57.37M
	EBITDA
16.16M	20.33M	10.33M	-87.60M	-57.37M
	Net Income Common Stockholders
12.09M	-92.93M	2.30M	-87.93M	-55.54M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
11.81M	33.51M	21.67M	46.85M	79.35M
	Total Assets
125.41M	116.54M	28.44M	55.66M	94.85M
	Total Debt
1.60M	409.00K	38.00K	2.38M	1.64M
	Net Debt
-10.21M	-33.10M	-21.63M	-41.96M	-28.72M
	Total Liabilities
27.00M	38.06M	50.13M	14.57M	18.78M
	Stockholders Equity
63.32M	-15.83M	-21.69M	41.09M	76.07M
Cash Flow		Free Cash Flow
-5.96M	17.31M	-38.09M	-84.59M	-55.31M
	Operating Cash Flow
-3.64M	25.89M	-33.10M	-83.75M	-55.05M
	Investing Cash Flow
-19.88M	-19.76M	55.43M	48.19M	9.66M
	Financing Cash Flow
2.10M	2.50M	-45.01M	49.55M	60.38M

Gyre Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 9.19
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GYRE, the sentiment is Neutral. The current price of 9.19 is above the 20-day moving average (MA) of 7.94, below the 50-day MA of 9.90, and below the 200-day MA of 11.91, indicating a neutral trend. The MACD of -0.42 indicates Negative momentum. The RSI at 50.03 is Neutral, neither overbought nor oversold. The STOCH value of 81.34 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GYRE.

Gyre Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.20B	3.26	-40.34%	2.93%	17.68%	1.94%
ABCL	49 Neutral	$730.07M	―	-14.75%	―	-24.17%	-9.24%
NRIX	47 Neutral	$873.66M	―	-64.16%	―	-30.25%	-5.92%
XERS	46 Neutral	$631.15M	―	222.83%	―	23.89%	16.86%
GYRE	45 Neutral	$745.91M	73.85	-57.18%	―	―	―
PHVS	40 Underperform	$822.30M	―	-41.43%	―	―	0.71%
NTLA	40 Underperform	$860.23M	―	-54.00%	―	59.55%	3.09%

Gyre Therapeutics Corporate Events

Gyre Therapeutics Faces Revenue Decline Amidst Future Prospects

GNI Group Ltd., which has an indirect controlling interest in Gyre Therapeutics, Inc., reported its financial results for the fiscal year ending December 31, 2024. The company, involved in pharmaceuticals and clinical trials, experienced a decline in revenue and profits compared to 2023. Despite this, GNI anticipates significant developments in 2025, including Phase 3 trial results for Hydronidone in China and other clinical advancements. These upcoming milestones could potentially enhance GNI’s position in the pharmaceuticals market, particularly in liver disease treatment.